- Diseases
- Acoustic Neuroma (14)
- Adrenal Gland Tumor (24)
- Anal Cancer (68)
- Anemia (2)
- Appendix Cancer (16)
- Bile Duct Cancer (28)
- Bladder Cancer (68)
- Brain Metastases (28)
- Brain Tumor (234)
- Breast Cancer (714)
- Breast Implant-Associated Anaplastic Large Cell Lymphoma (2)
- Cancer of Unknown Primary (4)
- Carcinoid Tumor (8)
- Cervical Cancer (158)
- Colon Cancer (166)
- Colorectal Cancer (106)
- Endocrine Tumor (4)
- Esophageal Cancer (40)
- Eye Cancer (36)
- Fallopian Tube Cancer (6)
- Germ Cell Tumor (4)
- Gestational Trophoblastic Disease (2)
- Head and Neck Cancer (2)
- Kidney Cancer (124)
- Leukemia (352)
- Liver Cancer (50)
- Lung Cancer (288)
- Lymphoma (286)
- Mesothelioma (14)
- Metastasis (30)
- Multiple Myeloma (102)
- Myelodysplastic Syndrome (64)
- Myeloproliferative Neoplasm (4)
- Neuroendocrine Tumors (16)
- Oral Cancer (102)
- Ovarian Cancer (172)
- Pancreatic Cancer (172)
- Parathyroid Disease (2)
- Penile Cancer (16)
- Pituitary Tumor (6)
- Prostate Cancer (146)
- Rectal Cancer (58)
- Renal Medullary Carcinoma (6)
- Salivary Gland Cancer (14)
- Sarcoma (234)
- Skin Cancer (294)
- Skull Base Tumors (54)
- Spinal Tumor (12)
- Stomach Cancer (58)
- Testicular Cancer (28)
- Throat Cancer (92)
- Thymoma (6)
- Thyroid Cancer (96)
- Tonsil Cancer (32)
- Uterine Cancer (78)
- Vaginal Cancer (14)
- Vulvar Cancer (18)
- Cancer Topic
- Adolescent and Young Adult Cancer Issues (20)
- Advance Care Planning (8)
- Advance Directives (4)
- Biostatistics (2)
- Blood Donation (18)
- Bone Health (8)
- COVID-19 (362)
- Cancer Recurrence (120)
- Childhood Cancer Issues (120)
- Clinical Trials (622)
- Complementary Integrative Medicine (20)
- Cytogenetics (2)
- DNA Methylation (4)
- Diagnosis (220)
- Epigenetics (6)
- Fertility (62)
- Follow-up Guidelines (2)
- Health Disparities (12)
- Hereditary Cancer Syndromes (126)
- Immunology (18)
- Li-Fraumeni Syndrome (8)
- Mental Health (114)
- Molecular Diagnostics (8)
- Pain Management (64)
- Palliative Care (8)
- Pathology (10)
- Physical Therapy (18)
- Pregnancy (18)
- Prevention (862)
- Research (402)
- Second Opinion (74)
- Sexuality (16)
- Side Effects (598)
- Sleep Disorders (10)
- Stem Cell Transplantation Cellular Therapy (216)
- Support (406)
- Survivorship (320)
- Symptoms (178)
- Treatment (1756)
Breast cancer patients who respond to chemo may not need surgery
2 minute read | Published May 09, 2017
Medically Reviewed | Last reviewed by an MD Anderson Cancer Center medical professional on May 09, 2017
Select breast cancer patients who after undergoing chemotherapy as their first line of treatment show no residual cancer – a state known as pathologic complete response (pCR) – may be able to avoid follow-up breast and lymph node surgery, according to an MD Anderson study. The study identifies patients known as “exceptional responders” who are at lowest risk for local metastases and therefore are candidates for less invasive treatments.
Henry Kuerer, M.D., Ph.D., professor of Breast Surgical Oncology, is principal investigator of the study that enrolled 527 women diagnosed with triple negative and HER-2 positive breast cancers. All the participants received neoadjuvant chemotherapy, in which chemo was their initial treatment, followed by standard breast and lymph node surgery. Clinical staging was determined prior to chemo by core biopsy or fine-needle aspiration, followed by clinical exam, mammography, and ultrasound of the breast and lymph nodes.
Kuerer set out to identify which patients in the group could have safely avoided surgery. To do so, he first needed to identify those who achieved a pCR following neoadjuvant chemo.
Kuerer had recently completed a trial investigating the utility of image-guided biopsies to predict breast pCR. The preliminary results of that study revealed the technique to have 100 percent accuracy and 100 percent predictive value for determining residual disease following neoadjuvant chemo.
“By doing the same image-guided needle biopsies after neoadjuvant chemo that we do at time of diagnosis, our preliminary research revealed we can accurately predict which women will have a complete response,” said Kuerer.
The current study tested participants using this technique, and showed that patients achieving a breast pCR were seven times less likely to have residual cancer in the lymph nodes
“Based upon these findings, we anticipate women with initial lymph node-negative disease may avoid breast and lymph node surgery if they achieve a pCR after neoadjuvant chemo and move on to standard radiotherapy,” said Audree Tadros, M.D., fellow in Breast Surgical Oncology and the study’s lead author.
Read more about this study in MD Anderson’s newsroom.